The proportions of patients whose progressive tumor tissue showed alterations (especially CNVs) in the genes TP53, RB1, and PTEN or in the genes involved in AR signaling pathways or in DDR were considerably higher than the corresponding proportions of patients whose ctDNA showed alterations in these genes (Fig. 1C). This evidence concerns the gene RB1 and neoplasm.